CoreCap Advisors’s Acer Therapeutics Inc ACER Stock Holding History

CoreCap Advisors’s Portfolio ACER Stock Details ACER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-96	Closed	-$1K	–	2251
2021 Q4	$1K	Buy	+96	New	+$223	﹤0.01%	2331

Other funds holding ACER

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

LFG

Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return

CoreCap Advisors's ACER Position: Q1 2022 in Review

CoreCap Advisors sold out of Acer Therapeutics Inc (ACER) in Q1 2022, closing a stake of 96 shares — an estimated $1K sold.

CoreCap Advisors first reported a position in ACER in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 21 funds tracked by Wall St. Rank hold ACER as of Q1 2022.

CoreCap Advisors reported no remaining Acer Therapeutics Inc position as of Q1 2022 after selling out during the quarter.
CoreCap Advisors sold 96 Acer Therapeutics Inc shares in Q1 2022, an estimated $1K.
CoreCap Advisors first reported a position in Acer Therapeutics Inc in Q4 2021 and held it in 1 quarter.
CoreCap Advisors's Acer Therapeutics Inc position peaked at $1K in Q4 2021.
21 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q1 2022.

Based on CoreCap Advisors's 13F filing for Q1 2022, filed 29 Apr 2022.